Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

Author： Tomao Federica   Papa Anselmo   Rossi Luigi   Caruso Davide   Zoratto Federica   Benedetti Panici Pierluigi   Tomao Silverio  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.23, Iss.1, 2014-01, pp. : 37-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on bevacizumab and other angiogenesis inhibitors for brain cancer

By Rinne Mikael L   Lee Eudocia Q   Nayak Lakshmi   Norden Andrew D   Beroukhim Rameen   Wen Patrick Y   Reardon David A  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 2, 2013-06 ,pp. : 137-153

Informa Healthcare

Access to resources Recommend Favorite

Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors

By  

Current Drug Targets, Vol. 18, Iss. 10, 2017-07 ,pp. : 1171-1178

Bentham Science Publishers

Access to resources Recommend Favorite

Bevacizumab costly for ovarian cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 624, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Angiogenesis Inhibitors: New Agents in Cancer Therapy

By Ryan C.J.  

Drugs & Aging, Vol. 17, Iss. 4, 2000-10 ,pp. : 249-255

Adis International

Access to resources Recommend Favorite

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

By Troiani Teresa   Martinelli Erika   Orditura Michele   De Vita Ferdinando   Ciardiello Fortunato   Morgillo Floriana  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 949-959

Informa Healthcare

Access to resources Recommend Favorite